Argos Therapeutics, Inc.
ARGS
ARGS was delisted on the 24th of April, 2018.
26 hedge funds and large institutions have $38.8M invested in Argos Therapeutics, Inc. in 2014 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 5 increasing their positions, 11 reducing their positions, and 7 closing their positions.
12% more capital invested
Capital invested by funds: $34.7M → $38.8M (+$4.06M)
13% less funds holding
Funds holding: 30 → 26 (-4)
55% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 11
57% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NI
Numeric Investors
Boston,
Massachusetts
|
+$288K |
| 2 |
HighTower Advisors
Chicago,
Illinois
|
+$195K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$152K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$133K |
| 5 |
PSI
Pinnacle Summer Investments
Fairfax,
Virginia
|
+$133K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PRCM
Pine River Capital Management
Minnetonka,
Minnesota
|
-$1.92M |
| 2 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
-$655K |
| 3 |
Alyeska Investment Group
Chicago,
Illinois
|
-$436K |
| 4 |
WSA
Wall Street Associates
Lajolla,
California
|
-$370K |
| 5 |
Caisse de Depot et Placement du Quebec (CDPQ)
Montreal,
Quebec, Canada
|
-$328K |
ARGS Hedge Fund Activity: Q3 2014 in Review
26 of the 3,448 institutional investors tracked by Wall St. Rank reported a position in Argos Therapeutics, Inc. (ARGS) for Q3 2014, worth a combined $38.8M — up 12% from $34.7M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of ARGS and 3 opened new positions — a net loss of 4 holders — while 11 trimmed existing stakes and 5 added.
The largest buyer was Numeric Investors, opening a new position worth an estimated $288K. The largest seller was Pine River Capital Management, exiting entirely with an estimated $1.92M sold.
- 26 institutional investors held Argos Therapeutics, Inc. (ARGS) as of Q3 2014, down from 30 in Q2 2014.
- Funds reported $38.8M of Argos Therapeutics, Inc. stock for Q3 2014, up 12% quarter-over-quarter.
- 3 funds opened new Argos Therapeutics, Inc. positions in Q3 2014 and 7 closed out, a net change of -4 holders.
- The largest Argos Therapeutics, Inc. buyer in Q3 2014 was Numeric Investors, an estimated $288K added.
- The largest Argos Therapeutics, Inc. seller in Q3 2014 was Pine River Capital Management, an estimated $1.92M sold.
Based on aggregated 13F filings for Q3 2014.